# Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

> **NCT02175004** · PHASE3 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 135 (actual)

## Conditions studied

- FAP
- Familial Amyloid Polyneuropathy
- TTR
- Transthyretin
- Amyloidosis

## Interventions

- **DRUG:** Inotersen

## Key facts

- **NCT ID:** NCT02175004
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-26
- **Primary completion:** 2020-09-11
- **Final completion:** 2021-01-07
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175004, "Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02175004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*